AR039757A1 - Derivados de tiofeno inhibidores de trombina - Google Patents

Derivados de tiofeno inhibidores de trombina

Info

Publication number
AR039757A1
AR039757A1 ARP030102305A ARP030102305A AR039757A1 AR 039757 A1 AR039757 A1 AR 039757A1 AR P030102305 A ARP030102305 A AR P030102305A AR P030102305 A ARP030102305 A AR P030102305A AR 039757 A1 AR039757 A1 AR 039757A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
hydrogen
nhr2
heteroaryl
Prior art date
Application number
ARP030102305A
Other languages
English (en)
Inventor
Suk Kyoon Yoon
Bong-Chan Kim
Sung-Ji Kim
Sangyeul Hwang
Hee Dong Park
Sun Hwa Lee
Ae Ri Kim
Ho Jun Kim
Su-Kyung Park
Koo Lee
Kunhye Nam
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR039757A1 publication Critical patent/AR039757A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuesto inhibidor de trombina que tiene un buen efecto inhibidor contra la trombosis y puede ser administrado oralmente, un procedimiento para preparar el mismo, y una composición para el tratamiento terapéutico y/o profiláctico de varias enfermedades asociadas con el mecanismo de inhibición de trombina, que comprende el mismo como un ingrediente activo. Reivindicación 1: Un compuesto representado por la fórmula (1), un isómero, un solvato, un hidrato o una sal farmacéuticamente aceptable del mismo, caracterizado porque: A representa -CH2CO2R1, en donde R1 representa hidrógeno, alquilo C1-6, cicloalquilo C3-7, alquilo C5-10-ar-C1-6, o arilo C5-10; B representa H, OH, R2, OR2, OC(O)R2, OC(O)NHR2, OC(O)OR2, C(O)OR2, C(O)R2, C(O)NHR2, C(O)NR22, OP(O)(OR3)2 o C(O)O(CHR4)mOC(O)R5; en donde: R1 y B no son hidrógeno al mismo tiempo; R2 y R5 independientemente uno de otro representan nitro, o representan alquilo C1-6 no sustituido o mono- a poli-sustituido por sustituyentes seleccionados entre un grupo que consiste en halógeno, hidroxi y alcoxi C1-6, o representa (CH2)n-cicloalquilo C3-7, (CH2)n-heteroarilo, (CH2)n-heterociclo (n = 0, 1, 2, 3) (en donde heteroarilo o heterociclo significa un anillo de 5 ó 6 miembros que tiene uno o dos heteroátomos seleccionados entre un grupo que consiste en nitrógeno, oxígeno y azufre) o representa fenilo no sustituido o mono- a poli-sustituido por sustituyentes seleccionados entre un grupo que consiste en halógeno, hidroxi y alcoxi C1-6, o representa alquilo C5-10-ar-C1-6, arilo C5-10 o alquilo C1-6-N(R4)2; m denota un número entero de 1, 2, 3 ó 4; R3 representa hidrógeno o alquilo C1-6; y R4 representa hidrógeno o alquilo C1-3.
ARP030102305A 2002-06-27 2003-06-26 Derivados de tiofeno inhibidores de trombina AR039757A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20020036219 2002-06-27

Publications (1)

Publication Number Publication Date
AR039757A1 true AR039757A1 (es) 2005-03-09

Family

ID=29997390

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102305A AR039757A1 (es) 2002-06-27 2003-06-26 Derivados de tiofeno inhibidores de trombina

Country Status (5)

Country Link
KR (1) KR20040002699A (es)
AR (1) AR039757A1 (es)
AU (1) AU2003245060A1 (es)
TW (1) TW200400187A (es)
WO (1) WO2004002985A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10294189B2 (en) * 2016-09-20 2019-05-21 Uchicago Argonne, Llc Process for producing fluorinated electrolyte solvent
AU2017348305B2 (en) 2016-10-31 2022-04-21 Biocryst Pharmaceuticals, Inc. Prodrugs of kallikrein inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501044A (ja) * 1998-01-26 2002-01-15 ビーエーエスエフ アクチェンゲゼルシャフト カリクレインプロテアーゼ阻害剤としての複素環アミジン
KR20000047461A (ko) * 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
WO2000061609A2 (de) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Prodrugs von thrombininhibitoren
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon

Also Published As

Publication number Publication date
WO2004002985A1 (en) 2004-01-08
TW200400187A (en) 2004-01-01
KR20040002699A (ko) 2004-01-07
AU2003245060A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
PE20020872A1 (es) DERIVADOS DE FENETANOLAMINA COMO AGONISTAS DE LOS ß2-ADRENORECEPTORES
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
AR033408A1 (es) Compuestos de bisarilo que contienen nitrogeno orto, orto-sustituidos, procedimientos para su preparacion, su utilizacion para la preparacion de un medicamento como tambien composiciones farmaceuticas que los contienen
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
EA200600892A1 (ru) Новые хинолиновые производные
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
AR039385A1 (es) Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY138906A (en) Phenyl derivatives as ppar agonists
AR039566A1 (es) Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion
CY1110986T1 (el) Αζολια ως αναστολεις της αποκαρβοξυλασης μηλονυλο-συνενζυμου α χρησιμα ως μεταβολικοι διαμορφωτες
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR068695A2 (es) Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa
UY27716A1 (es) Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo.
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
AR066972A1 (es) Derivados azapeptidicos
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CY1109085T1 (el) Νεα αλατα
ES2632798T3 (es) Uso de derivados de cumarina para la preparación de fármacos de tratamiento de enfermedades de la piel
ATE415395T1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure